• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Survival is similar for patients with autoimmune disease treated with immune checkpoint inhibitors compared to patients with no autoimmune disease

byJohan PushaniandSze Wah Samuel Chan
July 18, 2022
in Oncology, Rheumatology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. There was no significant difference in efficacy of ICIs in cancer patients with or without AID.

2. Immune-related toxic effects in AID patients was associated with an improved overall survival, but was the opposite for active AID patients.

Evidence Rating Level: 2 (Good)

Study Rundown: Immune checkpoint inhibitors (ICIs) can lead to immune-related adverse events. As such, patients with autoimmune disease are often excluded from clinical trials with ICIs due to concerns for increased toxicity. This study explored the efficacy and safety of ICIs in patients with cancer and autoimmune disease (AID), as well as the association of immune-related toxic effects (irTEs) with outcomes in a pancancer cohort. The most common AID diagnoses were psoriasis and rheumatoid arthritis. Equivalent rates of tumour response and overall survival were observed in patients with AID and without AID. However, patients with active AID (AID requiring systemic immunosuppression at ICI initiation) had poorer overall survival. In AID patients who experienced irTEs, there was an improved overall survival. Disease flares were mostly mild, whereby only a third of cases required systemic immunosuppression but nearly 60% experienced some of immune-related toxicity. Patients with active AID had more disease flares that those with latent disease. Limitations to this study include its retrospective design and the fact that this pancancer cohort may not be representative of all cancer types. The strength of this study is that it suggests there were no significant differences in response rates and survival in AID and non-AID patients, thereby suggesting that the AID cohort should be safe to include in clinical trials with ICIs. Overall, the efficacy and safety of ICIs are similar in cancer patients with and without AID.

Click to read the study in JAMA Oncology

Relevant Reading: Efficacy and toxicity of immune -checkpoint inhibitors in patients with preexisting autoimmune disorders

In-Depth [retrospective cohort]: This retrospective cohort study analyzed the records of 1822 patients with solid tumours who received ICIs or combination therapy (chemotherapy plus ICIs). Of these patients, 147 (8.1%) had AID. Most common AID diagnoses were psoriasis (38 patients) and rheumatoid arthritis (18 patients). Tumour response rates in the AID cohort was 28.6% and 25.7% in the non-AID cohort (P=0.43). No significant difference in overall survival between both cohorts was observed either (hazard ratio [HR], 0.95; 95% confidence interval [CI], 0.76 to 1.17; P=0.61). However, patients with active AID had poorer overall survival (HR, 2.81; 95% CI, 1.41 to 5.58; P=0.003). Overall survival was higher for AID patients with irTEs (HR, 0.55; 95% CI, 0.32 to 0.95; P=0.03). Mild disease flares occurred in most patients; 81% were of grade 1, 19% were of grade 2, and 33% were of grade 3. Only 33% of patients with disease flares needed systemic immunosuppression. Patients with active AID had more flares (60% vs. 22.1%; P<0.001). Overall, safety and efficacy of ICIs on AID cancer patients was similar to non-AID patients, with irTEs being associated with more higher immunotherapy efficacy.

RELATED REPORTS

#VisualAbstract: FOLFOX in combination with nivolumab and trastuzumab improves survival in metastatic ERBB2⁺ esophagogastric adenocarcinoma

#VisualAbstract: Pembrolizumab reduces disease recurrence in completely resected stage IIB/IIC melanoma

#VisualAbstract: Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: autoimmune diseaseimmune-related adverse event (irAE)immunotherapy
Previous Post

The effectiveness of motor control training in lumbar disc herniation patients remains uncertain

Next Post

Breast, colorectal, and cervical cancer screening was reduced during the COVID-19 pandemic as compared to pre-COVID time periods.

RelatedReports

#VisualAbstract: Concurrent use of tamoxifen with direct oral anticoagulants is not associated with an increased risk of hemorrhage
StudyGraphics

#VisualAbstract: FOLFOX in combination with nivolumab and trastuzumab improves survival in metastatic ERBB2⁺ esophagogastric adenocarcinoma

July 20, 2022
#VisualAbstract: Pembrolizumab reduces disease recurrence in completely resected stage IIB/IIC melanoma
StudyGraphics

#VisualAbstract: Pembrolizumab reduces disease recurrence in completely resected stage IIB/IIC melanoma

July 12, 2022
#VisualAbstract: Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer
StudyGraphics

#VisualAbstract: Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer

April 28, 2022
Women electing abortion more likely to be victims of domestic violence
Chronic Disease

Prenatal exposure to maternal autoimmune diseases associated with increased risks of mental disorders in offspring

April 20, 2022
Next Post
Patient Basics: Colonoscopy

Breast, colorectal, and cervical cancer screening was reduced during the COVID-19 pandemic as compared to pre-COVID time periods.

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

Third dose of BNT162b2 COVID-19 vaccine effective at decreasing risk of hospitalization [Classics Series]

AAP recommends disaster preparedness measures for children

Children’s physical activity significantly decreased during the COVID-19 pandemic

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Delta variant of SARS-CoV-2 infection associated with higher changes of severe maternal morbidities
  • Endoscopic sleeve gastroscopy effective for excess weight loss in type 1 and 2 obesity
  • #VisualAbstract: Early time-restricted eating was more effective for weight loss than eating over 12-hour window
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.